Localized AL amyloidosis
- Authors: Kashchavtseva N.A.1, Rekhtina I.G.1, Kovrigina A.M.1,2, Danilina T.P.1, Mendeleeva L.P.1
-
Affiliations:
- National Medical Research Center for Hematology
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 97, No 3 (2025): Пульмонология
- Pages: 257-262
- Section: Clinical notes
- URL: https://journal-vniispk.ru/0040-3660/article/view/290999
- DOI: https://doi.org/10.26442/00403660.2025.03.203136
- ID: 290999
Cite item
Full Text
Abstract
Localized light chain (AL) amyloidosis (amyloidoma) is a rare disease with unclear pathogenesis and undeveloped approaches to therapy. This article presents 3 clinical observations of localized AL amyloidosis with lesions of the respiratory tract, eyes, and soft tissues of the face. Tumor masses consisted of amyloid masses in which single monotypic plasma cells were "embedded". To verify the cell substrate, the method of chromogenic in situ hybridization with probes to immunoglobulin light chains was used. Amyloid typing was performed using FITC-labeled antibodies to kappa and lambda light chains after enzymatic treatment of paraffin sections with pronase. The absence of monoclonal secretion (in two cases) made it difficult to assess the efficacy of the therapy. Taking into account the prevalence and severity of vital organs damage, as well as the recurrent nature of the disease course, systemic combination therapy with targeted drugs was prescribed. Stabilization of the process in all patients was stated during one year of follow-up. Nevertheless, clonreducing therapy in localized AL amyloidosis is not considered as a standard option, its feasibility and efficacy requires further confirmation.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Nelly A. Kashchavtseva
National Medical Research Center for Hematology
Author for correspondence.
Email: kashchavtseva.n@blood.ru
ORCID iD: 0009-0001-9235-7853
врач-гематолог отд-ния химиотерапии плазмоклеточных дискразий
Russian Federation, MoscowIrina G. Rekhtina
National Medical Research Center for Hematology
Email: kashchavtseva.n@blood.ru
ORCID iD: 0000-0001-5440-4340
доктор медицинских наук, зав. отделением химиотерапии плазмоклеточных дискразий
Russian Federation, MoscowAlla M. Kovrigina
National Medical Research Center for Hematology; Sechenov First Moscow State Medical University (Sechenov University)
Email: kashchavtseva.n@blood.ru
доктор биол. наук, профессор, зав. патологоанатомическим отделением
Russian Federation, Moscow; MoscowTatyana P. Danilina
National Medical Research Center for Hematology
Email: kashchavtseva.n@blood.ru
ORCID iD: 0000-0001-8877-9458
врач-патологоанатом патологоанатомического отд-ния
Russian Federation, MoscowLarisa P. Mendeleeva
National Medical Research Center for Hematology
Email: kashchavtseva.n@blood.ru
ORCID iD: 0000-0002-4966-8146
доктор медицинских наук, профессор, зав. отд. химиотерапии парапротеинемических гемобластозов, рук. управления по научной и образовательной работе
Russian Federation, MoscowReferences
- Palladini G, Schönland S, Merlini G, et al. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13(1):19. doi: 10.1038/s41408-023-00789-8
- Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71-80. doi: 10.1182/blood.2019004460
- Kourelis TV, Kyle RA, Dingli D, et al. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. Mayo Clin Proc. 2017;92(6):908-17. doi: 10.1016/j.mayocp.2017.02.016
- Basset M, Hummedah K, Kimmich C, et al. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. Am J Hematol. 2020;95(10):1158-19. doi: 10.1002/ajh.25915
- Mahmood S, Bridoux F, Venner CP, et al. Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematol. 2015;2(6):e241-50. doi: 10.1016/S2352-3026(15)00068-X
- Тао П.П., Рамеев В.В., Рамеева А.С., и др. Проблемы диагностики и лечения локального AL амилоидоза. Клиническая фармакология и терапия. 2019;28(3):39-46 [Tao PP, Rameev VV, Rameeva AS, et al. Diagnosis and treatment of localized AL-amyloidosis. Clinical Pharmacology and Therapy. 2019;28(3):39-46 (in Russian)]. doi: 10.32756/0869-5490-2019-3-39-46
- Dabholkar YG, Wadhwa A, Verma B. Isolated Primary Laryngeal Amyloidosis: A Case Series of a Rare Presentation of Change in Voice. An International Journal of Otorhinolaryngology Clinics. 2021;13(2):73-5. doi: 10.5005/jp-journals-10003-1384
Supplementary files
